Roth Capital initiated coverage of ProMIS Neurosciences with a Buy rating and $19 price target. The firm attributes its bullish view to PMN310's unique MoA targeting toxic oligomers implicated in Alzheimer's disease, positive preclinical data showing cognition benefits, and potential for low ARIA/less frequent MRI monitoring vs. approved AD-antibodies,the analyst tells investors in a research note. ProMIS's current cash at $64M could also support operations into 2027, with potential for $100M warrant exercise upon positive Phase 1b data, the firm added.
